European Pharmaceutical Review

NOVEMBER 24, 2022

Nivolumab (Opdivo), together with chemotherapy has been recommended in the National Institute for Health and Care Excellence NICE final draft guidance for untreated HER2-negative, advanced or metastatic gastric, gastroesophageal junction (GEJ) or oesophageal adenocarcinoma where tumours express programmed death-1 receptor (PD-L1).

Chemotherapy 95

Chemotherapy Immunization 95

Hospital Pharmacy Europe

FEBRUARY 29, 2024

Adding an arginine-depleting agent to chemotherapy extends survival for patients with advanced non-epithelial pleural mesothelioma, a randomised controlled trial suggests. Pegargiminase-based chemotherapy was well tolerated, with no new safety signals, they added. mg/ m2) or placebo. mg/ m2) or placebo.

Chemotherapy 52

Chemotherapy Immunization Hospitals 52

STAT

NOVEMBER 29, 2023

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation.

Chemotherapy 125

Chemotherapy Immunization FDA 125

STAT

DECEMBER 12, 2023

This approach has been around for decades but required patients to have a well-matched donor and endure a hefty dose of chemotherapy, ruling out transplant as an option for the vast majority of patients.

Chemotherapy 127

Chemotherapy Immunization 127

European Pharmaceutical Review

OCTOBER 1, 2022

A Phase III trial from Shanghai Henlius Biotech is the first study to suggest that the programmed cell death (PD) 1 receptor immune checkpoint inhibitor Hansizhuang (serplulimab) plus chemotherapy can markedly improve survival for extensive-stage small cell lung cancer (ES-SCLC) patients. A follow-up after 12.3 months).

Chemotherapy 87

Chemotherapy Immunization Hospitals 87

STAT

JUNE 6, 2023

Novocure’s study achieved its primary goal and showed a survival benefit for patients with lung cancer that progressed following initial chemotherapy.

Chemotherapy 100

Chemotherapy Immunization 100

European Pharmaceutical Review

MAY 17, 2023

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.

Immunization 81

Immunization Chemotherapy 81

STAT

APRIL 11, 2024

These include oxytocin, which is used during childbirth; Rho(D) immune globulin, which helps some women during pregnancy; standard-of-care chemotherapy, pain and sedation medicines; and ADHD pills. Continue to STAT+ to read the full story…

Chemotherapy 76

Chemotherapy Immunization 76

European Pharmaceutical Review

DECEMBER 21, 2022

Having patients in the trial achieve full T-cell immunity is outstanding. Researchers predicted Artemis-SCID patients would need less chemotherapy to prepare their marrow for transfusion when their own cells were being used, so only 25 percent of a full dose of busulfan was administered.

Immunization 102

Immunization Chemotherapy Vaccines 102

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results. Then 487 were part of the BV-AVD group.

Chemotherapy 82

Chemotherapy Immunization 82

Pharmafile

JANUARY 27, 2023

The antibody treatment was previously used as an additional layer of protection against the virus for those with compromised immune systems, such as those undergoing chemotherapy, or organ-transplant patients. read more

FDA 52

FDA Chemotherapy Immunization Communication 52

Pharmaceutical Technology

NOVEMBER 24, 2022

The National Institute for Health and Care Excellence (NICE) in the UK has recommended Bristol Myers Squibb ’s (BMS) nivolumab (Opdivo) plus chemotherapy as an option for patients with advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma. The PD-1 protein can switch off the immune system of the body.

Chemotherapy 52

Chemotherapy Immunization 52

European Pharmaceutical Review

DECEMBER 12, 2023

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

Immunization 106

Immunization Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 106

Hospital Pharmacy Europe

AUGUST 23, 2023

A human CD40 agonistic antibody targeting CD40, mitazalimab kickstarts the cancer-immunity cycle by priming and activating tumour-specific T cells. Targeting CD40 with mitazalimab has the potential to augment responses to chemotherapy.

Chemotherapy 98

Chemotherapy Immunization Hospitals FDA 98

European Pharmaceutical Review

SEPTEMBER 25, 2023

The humanised IgG4 anti-PD-1 antibody is indicated for unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy. The treatment is currently under review by the US FDA and the European Medicines Agency (EMA) for advanced or metastatic ESCC after prior chemotherapy.

Chemotherapy 89

Chemotherapy FDA Immunization 89

Pharmaceutical Technology

NOVEMBER 13, 2022

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) and platinum-based chemotherapy to treat Stage IV (metastatic) non-small cell lung cancer (NSCLC) in adults.

FDA 52

FDA Chemotherapy Labelling Immunization 52

pharmaphorum

SEPTEMBER 11, 2022

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

Chemotherapy 105

Chemotherapy Immunization Hospitals 105

pharmaphorum

JANUARY 3, 2023

Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported. Once no cure can be found for a patient’s condition, decisions must be made about what is the most suitable path forwards.

Chemotherapy 105

Chemotherapy Immunization Hospitals 105

European Pharmaceutical Review

JANUARY 26, 2023

CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Could CAR T therapies be manufactured in one day?

Chemotherapy 118

Chemotherapy Immunization 118

pharmaphorum

MAY 30, 2022

“An antibody-drug conjugate is where you connect and link a chemotherapy to an antibody,” Verma said. So there’s a Trojan horse-like mechanism to deliver chemotherapy right to the cancer cell.”. While directed chemotherapy isn’t totally free of side effects, it reduces them.

Chemotherapy 116

Chemotherapy Immunization 116

European Pharmaceutical Review

DECEMBER 28, 2023

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

Immunization 84

Immunization Chemotherapy Medical Schools FDA 84

pharmaphorum

NOVEMBER 29, 2022

Tecentriq is a monoclonal antibody designed to bind with PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blockings its interactions with both PD-1 and B7.1 Patients given the Tecentriq plus chemotherapy combination survived a median of 16 months after treatment, compared with 13.4

Chemotherapy 52

Chemotherapy FDA Immunization 52

European Pharmaceutical Review

AUGUST 25, 2022

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. After surgery, strategic combinations of radiotherapy, chemotherapy like temozolomide, and other forms of treatment, such as immunotherapy or the use of an electric field cap, are employed.

Immunization 98

Immunization Chemotherapy Packaging 98

Pharmaceutical Technology

MARCH 6, 2023

Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).

Chemotherapy 52

Chemotherapy FDA Labelling Immunization 52

European Pharmaceutical Review

MAY 12, 2023

High-magnitude vaccine-induced T cell responses, the focus of the immune response analysis that included a new method to track vaccine-expanded clones, correlated with delayed PDAC recurrence. The personalised neoantigen vaccine was based on uridine mRNA–lipoplex nanoparticles. Rojas et al.

Vaccines 90

Vaccines Immunization Chemotherapy 90

pharmaphorum

OCTOBER 22, 2021

The European Commission has given a green light to Opdivo (nivolumab) with chemotherapy for previously-untreated patients with HER2-negative oesophageal, gastric and gastroesophageal junction (GEJ) cancer whose tumours express the PDL-1 biomarker with a score of five or more. months compared to 11.4 months, respectively.

Chemotherapy 105

Chemotherapy Immunization FDA 105

European Pharmaceutical Review

SEPTEMBER 29, 2023

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Immunization 102

pharmaphorum

JANUARY 19, 2022

EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone.

Chemotherapy 59

Chemotherapy Immunization 59

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. Cancer Ther. 2020; 19(10): 2044–56.

Immunization 91

Immunization Chemotherapy FDA 91

pharmaphorum

SEPTEMBER 6, 2022

The Nijmegen, Netherlands-based biotech was founded in 2018 to develop therapies designed to change the balance of protein expression within the tumour ‘microenvironment’, which can defend cancers against the immune system, and is increasingly becoming a source of new targets in oncology. The Series A round includes €3.6

Chemotherapy 102

Chemotherapy Immunization FDA 102

European Pharmaceutical Review

JULY 12, 2022

By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Immunization 91

Immunization Chemotherapy 91

Hospital Pharmacy Europe

OCTOBER 20, 2023

Administered as an intravenous infusion, it works by encouraging healthy immune cells in the body to destroy the cancer cells. By bringing these cells together, the patient’s own immune system is activated and kills the cancer cell and so chemotherapy is not required.

Chemotherapy 52

Chemotherapy Immunization Hospitals 52

Pharmaceutical Technology

JULY 8, 2022

Xenetic has obtained exclusive intellectual property licence for usage of DNases in oncology including systemic co-administration of DNases along with standard treatments, such as chemotherapy, radiation and checkpoint inhibitors, or in combination with standard chimeric antigen receptor (CAR) T therapies.

Chemotherapy 59

Chemotherapy Immunization 59

The Checkup by Singlecare

SEPTEMBER 12, 2023

The Shingrix vaccine triggers the immune system to respond to the varicella virus and suppress the outbreak of shingles,” says David Cutler , MD, a family medicine physician at Providence Saint John’s Health Center in Santa Monica, California. This is a typical immunization response as your body builds a defense against possible infection.

Vaccines 105

Vaccines Immunization Pharmacy Program Director Chemotherapy 105

The Checkup by Singlecare

DECEMBER 29, 2022

Meaning, they may be caused by the immune system or other factors. . Immunologic reactions are reactions that involve a response by the immune system to a drug. Nonimmunologic reactions are reactions that don’t involve the immune system and are not typically considered true allergic reactions. Chemotherapy .

Adverse Reactions 98

Adverse Reactions Chemotherapy Immunization Dosage 98

pharmaphorum

JANUARY 26, 2023

The cancer is particularly challenging for immunotherapy, as it tends to have fewer mutations than other cancers, presenting fewer targets for immune cells, and tends to be immunologically ‘cold’, with few immune cells infiltrating the tumour. It remains ongoing with updated results due in the coming months.

Chemotherapy 59

Chemotherapy Immunization FDA 59

pharmaphorum

MAY 25, 2022

The health technology assessment (HTA) body has published draft guidance supporting routine NHS use of Keytruda (pembrolizumab) along with chemotherapy in patient with metastatic TNBC whose tumours express the biomarker PD-L1 with a combine positive score (CPS) of 10 or more.

Chemotherapy 64

Chemotherapy Immunization 64